Zanubrutinib May Benefit Patients With IgG4-Related Disease

Zanubrutinib monotherapy may help shrink inflamed glands, ease symptoms, and is generally well tolerated in patients with immunoglobulin G4-related head and neck disease, a phase 2 study shows.
Medscape Medical News